Our team has been together since 2003, and has ever since enabled clients to develop and obtain regulatory approval for their programs in Japan without significant delay compared to the US and EU.
Our team of experts understands the challenges of developing drugs for Japan, both on a standalone basis and through partnerships, and can assist our clients design new strategies, or support the assessment of existing plans, for Japan. We look forward to enabling you to achieve your strategic goals for Japan
IDEC offers its professional services to become the “Virtual R&D Team" for our clients, focusing on providing high value-added R&D services to independently design and confirm development strategies to support our clients’ decision making process, as well as to provide hands-on implementation capabilities to lead Japanese development programs with CROs and other local Japanese constituents.
|Company Name||IDEC Inc.|
|Address||Shinjuku i-Land Tower 41F, 6-5-1 Nishi-Shinjuku, Shinjuku-ku 163-1341 Tokyo Japan
Access Map Download
|Paid-in Capital||50,000,000 Yen|
|Founder and CEO||Chris Brünger, MD|
|# of Professionals*||25
* Includes contracted professional consultants
|Core Services||Professional regulatory and development consulting for Japan|
|Core Therapeutic Areas||Oncology, Immunology, CNS|
|Memberships||Kansai Pharmaceutical Industries Association
Pharma Delegates of Japan
DIA – Drug Information Association